In this full November 2–8 recap, 44% of treated patients in Vir's hepatitis delta trial met the Phase 3 primary endpoint, with an important difference in when the comparison groups were measured. CVS plans to separate its retail pharmacies and MinuteClinic from Aetna and Caremark, subject to conditions. Alex and Maya also examine HOVON 150 in IDH1-mutated leukemia, FDA's Zolgensma safety investigation, cardiovascular data and the week's deals and manufacturing news — and what the evidence does and does not show.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →